Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/ATTR Amyloidosis (Transthyretin Amyloidosis)

Metabolic & Lysosomal

ATTR Amyloidosis (Transthyretin Amyloidosis) Clinical Trials

Also called ATTR Amyloidosis, Transthyretin amyloidosis, TTR amyloidosis, Hereditary ATTR, hATTR, ATTR cardiomyopathy, ATTR-CM, ATTR polyneuropathy, ATTR-PN, Familial amyloid polyneuropathy, FAP, Hereditary Transthyretin Amyloidosis

ATTR amyloidosis develops when transthyretin protein misfolds and accumulates as amyloid deposits in organs throughout the body. In hereditary ATTR, a genetic mutation causes TTR protein instability. In wild-type ATTR, normal protein becomes unstable with age. Cardiac involvement causes restrictive cardiomyopathy, while neurological involvement produces peripheral and autonomic neuropathy.

In plain words, ATTR amyloidosis happens when a protein called transthyretin folds the wrong way and builds up in the heart, nerves and other organs. Some people inherit it while others develop it on their own, and it can lead to heart failure and nerve damage.

Get an email when new ATTR Amyloidosis (Transthyretin Amyloidosis) trials open or the FDA decides. Get alerts

ATTR Amyloidosis (Transthyretin Amyloidosis)

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review0

No decision pending. FDA calendar

FDA-approved medicines5

Amvuttra · Attruby · Onpattro · Vyndamax · Wainua

ATTR Amyloidosis (Transthyretin Amyloidosis) has 5 FDA-approved medicines, 40 open or active clinical trials, and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for ATTR Amyloidosis (Transthyretin Amyloidosis)

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about ATTR Amyloidosis (Transthyretin Amyloidosis)

For the heart form, most people are diagnosed without a biopsy: once blood and urine tests rule out AL amyloidosis, a PYP, DPD or HMDP bone scan showing grade 2 or 3 heart uptake confirms ATTR, and TTR gene sequencing separates hereditary from wild-type. The nerve form usually needs nerve testing, a tissue biopsy and genetic testing. A TTR variant alone does not confirm the disease; carriers are monitored, usually starting 10 years before the age their relatives got sick. Early detection through screening of at-risk populations is crucial since treatments work best when started early.

Keep reading about ATTR Amyloidosis (Transthyretin Amyloidosis)

Multiple FDA-approved therapies now address ATTR amyloidosis. TTR stabilizers like tafamidis and acoramidis prevent protein misfolding and aggregation. Gene-silencing therapies including vutrisiran and eplontersen reduce TTR production. Ongoing research focuses on TTR depleters that remove existing amyloid deposits.

What are the symptoms of ATTR Amyloidosis (Transthyretin Amyloidosis)?

These are common symptoms of ATTR Amyloidosis (Transthyretin Amyloidosis), and how strong they are varies from person to person.

  • Shortness of breath and progressive heart failure
  • Irregular heartbeat and atrial fibrillation
  • Leg swelling (edema) and fluid retention
  • Peripheral neuropathy with tingling, numbness, or weakness in feet and legs
  • Lightheadedness or fainting from cardiac conduction problems
  • Autonomic dysfunction including low blood pressure on standing and GI issues

Who gets ATTR Amyloidosis (Transthyretin Amyloidosis)?

Hereditary ATTR typically emerges in middle age, though onset varies significantly by geographic region and specific mutation. About 3-4% of African Americans carry the Val122Ile (V122I) variant. Wild-type ATTR predominantly affects males over 60.

Next steps: find trials you might fitcompare treatmentsget help payingget alerts

Which medicines are FDA-approved for ATTR Amyloidosis (Transthyretin Amyloidosis)?

There are currently 5 FDA-approved medications for ATTR Amyloidosis (Transthyretin Amyloidosis).

Side by sideCompare all 5 side by sideHow each of the medicines is taken, what the trials showed and the warnings on the label, in plain language.Open the comparison
Just prescribed one of these?Your first 90 days, step by stepWhat happens before the first fill, the tests and refills to expect, and help paying, with a one-page handout to print.
vutrisiran
Your first 90 days
Alnylam Pharmaceuticals
Official site
acoramidis
Your first 90 days
BridgeBio Pharma
Search
patisiran
Your first 90 days
Alnylam Pharmaceuticals
Official site
eplontersen
Your first 90 days
AstraZeneca (with Ionis Pharmaceuticals)
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Which new ATTR Amyloidosis (Transthyretin Amyloidosis) medicines are in trials?

Investigational medicines Trial Friend tracks for ATTR Amyloidosis (Transthyretin Amyloidosis), with trial results, safety findings and where each one stands.

How to get help paying for ATTR Amyloidosis (Transthyretin Amyloidosis) treatment

Charity funds and drugmaker programs for ATTR Amyloidosis (Transthyretin Amyloidosis), checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · NORD RareCare
    Amyloidosis Medical Assistance fund
    Waitlist

    Pays for: Medical and medication costs.

    The foundation says: “Temporarily Waitlisting”
  • From a charity · NORD RareCare
    Amyloidosis Premium Copay Assistance fund
    Waitlist

    Pays for: Insurance premiums and copays.

    The foundation says: “Temporarily Waitlisting”
  • From a charity · The Assistance Fund
    Amyloidosis fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 16, 2026.

Every program and fund for ATTR Amyloidosis (Transthyretin Amyloidosis), by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for ATTR Amyloidosis (Transthyretin Amyloidosis)

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

The TTR gene page lists every condition Orphanet links to the gene and the open trials that name it.

Finding labs...

Trusted ATTR Amyloidosis (Transthyretin Amyloidosis) resources

Reputable organizations and medical references for learning more about ATTR Amyloidosis (Transthyretin Amyloidosis), including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for ATTR Amyloidosis (Transthyretin Amyloidosis)

Use this ATTR Amyloidosis (Transthyretin Amyloidosis) clinical trial finder to see the 13 studies recruiting patients and 2 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 8 test a treatment and 7 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map, the pipeline timeline or the medication checker.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

40 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 4Recently updatedNCT07695701

Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

Intervention: Acoramidis (AG10) oral tablet

Sponsor: Eidos Therapeutics, a BridgeBio company

The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

Ages 18 Years to 80 Years
Started Jul 2026Updated 2 days agoEst. Aug 2030 (~3y 9m)
RecruitingObservational study, no treatment givenRecently updatedNCT07358078

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

Sponsor: Alnylam Pharmaceuticals

The purpose of this study is to:

* Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care

Ages 18 Years+
Started Jan 2026Updated 2 days agoEst. Oct 2030 (~3y 11m)
RecruitingObservational study, no treatment givenRecently updatedNCT04561518

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Sponsor: Alnylam Pharmaceuticals

The purpose of this study is to:

* Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients

Ages not specified
Started Nov 2020Updated 2 days agoEst. Dec 2033 (~7y 1m)
RecruitingObservational study, no treatment givenRecently updatedNCT05040373

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Sponsor: Alnylam Pharmaceuticals

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.

Ages not specified
Started Aug 2020Updated 2 days agoEst. Oct 2030 (~3y 10m)
RecruitingTreatment trialPhase 3Recently updatedNCT07223203

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Intervention: Nucresiran, Vutrisiran

Sponsor: Alnylam Pharmaceuticals

The purpose of this study is to:

* Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed

Ages 18 Years to 85 Years
Started Feb 2026Updated 3 days agoEst. Dec 2027 (~1y 1m)
Find ATTR Amyloidosis (Transthyretin Amyloidosis) trials near you, ranked by distance →
Active trial locations87 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+79 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 3
Phase 4
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about ATTR Amyloidosis (Transthyretin Amyloidosis) trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run an ATTR Amyloidosis (Transthyretin Amyloidosis) foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

ATTR Amyloidosis (Transthyretin Amyloidosis) patient communities

Facebook groups, Reddit communities and YouTube channels where ATTR Amyloidosis (Transthyretin Amyloidosis) patients, caregivers and advocacy groups talk.

ATTR Amyloidosis (Transthyretin Amyloidosis) news and guides

Trial Friend articles about ATTR Amyloidosis (Transthyretin Amyloidosis), newest first

Companies developing ATTR Amyloidosis (Transthyretin Amyloidosis) treatments

Drugmakers that list ATTR Amyloidosis (Transthyretin Amyloidosis) in their rare disease portfolio, 10 in all.

Questions people ask about ATTR Amyloidosis (Transthyretin Amyloidosis)